SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Amexdrug Corporation (AXRX) trades at a trailing P/E of 1.0. Trailing earnings yield is 100.00%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (1.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); earnings yield beats bond yields (100.00%).
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 100.00% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 63/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AXRX
Valuation Multiples
P/E (TTM)1.0
Forward P/EN/A
PEG Ratio0.01
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.01
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.02
FCF / Share$0.00
Yields & Fair Value
Earnings Yield100.00%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$0.00 |
$8.85M |
$100.31K |
1.1% |
| 2016 |
$0.00 |
$9.3M |
$73.76K |
0.8% |
| 2017 |
$0.00 |
$10.43M |
$111.36K |
1.1% |
| 2018 |
$0.00 |
$10.51M |
$201.4K |
1.9% |
| 2019 |
$0.00 |
$7.72M |
$216.89K |
2.8% |
| 2020 |
$0.00 |
$6.37M |
$195.99K |
3.1% |
| 2021 |
$0.04 |
$4.82M |
$74.19K |
1.5% |
| 2023 |
$0.00 |
$3.92M |
$35.83K |
0.9% |
| 2024 |
$0.00 |
$3.4M |
$11.44K |
0.3% |
| 2025 |
$0.00 |
$2.9M |
$40.28K |
1.4% |
